NPY1R — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL113377	1.00	20/20
SCHEMBL159369	1.00	20/20
SCHEMBL161992	1.00	20/20
SCHEMBL162002	1.00	20/20
SCHEMBL165710	0.82	20/20
SCHEMBL165591	0.81	20/20
SCHEMBL160447	0.75	20/20
SCHEMBL163824	0.60	18/20
SCHEMBL159462	0.60	17/20
SCHEMBL165736	0.54	17/20
SCHEMBL164025	0.53	16/20
SCHEMBL166049	0.51	15/20
SCHEMBL241711	0.64	11/20
SCHEMBL241712	0.64	11/20
Leupeptin (SCHEMBL25361)	0.51	11/20
Kyotorphin (SCHEMBL248288)	0.62	9/20
Kyotorphin (SCHEMBL248289)	0.62	9/20
Acetic Acid (SCHEMBL230814)	0.55	9/20
Acetic Acid (SCHEMBL230815)	0.55	9/20
SCHEMBL268375	0.69	8/20

Clinical trials — most relevant to NPY1R by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Divalproex Sodium on Food Intake, Energy Expenditure, and Posture Allocation	PHASE4	COMPLETED
Medication, Weight Gain and GI Hormones	PHASE4	COMPLETED
Saxenda: Underlying Mechanisms and Clinical Outcomes	PHASE4	ACTIVE_NOT_RECRUITING
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep	PHASE3	COMPLETED
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity	PHASE3	COMPLETED
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)	PHASE3	COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
Effects of Exenatide on Hypothalamic Obesity	PHASE1/PHASE2	COMPLETED
Intranasal Administration of Neuropeptide Y in Healthy Male Volunteers	PHASE2	COMPLETED
Repurposing Semaglutide for the Treatment of Cocaine Use Disorder	PHASE2	RECRUITING
Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)	PHASE2	COMPLETED
Neuropeptide Y and Sympathovagal Balance	EARLY_PHASE1	COMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma	nan	COMPLETED
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors	nan	COMPLETED
Acylated Ghrelin Response to Acute Exercise in Obesity	nan	COMPLETED
The Effect of Weekly Semaglutide Treatment on Energy Expenditure	nan	COMPLETED
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Functional MRI Evaluation of Brain Response to Visual Food Stimulation in Morbidly Obese Patients Before and After Bariatric Surgery	nan	COMPLETED
The Progress of Diabetes After Supaglutide Treatment in Type 2 Diabetes Patients	nan	RECRUITING
GLP-1 Receptor Expression in CHI	nan	UNKNOWN
Macronutrient Regulation of Ghrelin and Peptide YY	nan	COMPLETED
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention	nan	NOT_YET_RECRUITING
Effect of Fermentable Carbohydrate on Glucose Homeostasis	nan	COMPLETED
The Role of Peptide YY (PYY)in Inhibiting Food Intake.	nan	COMPLETED
Sex Differences in Neuropeptide Y Serum, But Not in Fat Intake and Body Mass Index	nan	COMPLETED
Brain-Derived Neurotrophic Factor in Obesity and Brain Function	nan	COMPLETED
The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes	nan	COMPLETED
Colonic Propionate, Appetite, and Weight Loss	nan	COMPLETED
Laparoscopic Single Anastomosis Sleeve Ileal Bypass Versus Laparoscopic Sleeve Gastrectomy For Morbidly Obese Patients	nan	UNKNOWN
Impact of Sleep and Meal Timing on Food Intake Regulation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NPY1R binder may also engage these)

Protein	Name	Similarity
O02835	—	1.000	O02835 →
O02813	—	1.000	O02813 →
Q1RMU8	—	1.000	Q1RMU8 →
Q04573	—	1.000	Q04573 →
P21555	—	1.000	P21555 →
Q9WVD0	—	0.997	Q9WVD0 →
P34992	—	0.991	P34992 →
Q9DDN6	—	0.981	Q9DDN6 →
NPY2R	Neuropeptide Y receptor type 2	0.979	landscape →
P79113	—	0.976	P79113 →
Q9GK74	—	0.976	Q9GK74 →
Q5IS62	—	0.975	Q5IS62 →
O02836	—	0.975	O02836 →
Q9Z2D5	—	0.973	Q9Z2D5 →
P97295	—	0.971	P97295 →
P79217	—	0.967	P79217 →
Q61041	—	0.966	Q61041 →
Q61212	—	0.966	Q61212 →
Q924H0	—	0.966	Q924H0 →
Q56H79	—	0.965	Q56H79 →
PROKR2	Prokineticin receptor 2	0.965	landscape →
Q8SPN1	—	0.965	Q8SPN1 →
Q9NYM4	—	0.965	Q9NYM4 →
O62809	—	0.965	O62809 →
P47751	—	0.964	P47751 →
Q8BZP8	—	0.963	Q8BZP8 →
Q63447	—	0.963	Q63447 →
Q8K458	—	0.963	Q8K458 →
P30731	—	0.962	P30731 →
HCRTR2	Orexin receptor type 2	0.962	landscape →